Evaluating immune system aging in lupus patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the phenomenon of immune system aging in patients with systemic lupus erythematosus (SLE). It aims to compare the immune aging processes in SLE patients to age-matched healthy controls, focusing on the potential acceleration of immunosenescence in this population. By collecting blood samples and assessing various disease activity markers, the study seeks to understand how aging impacts the health outcomes of SLE patients. The research is conducted at Bordeaux University Hospital with a target enrollment of 50 participants.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* male or female;
* age between 18 and 60 years;
* Lupus patient : diagnosis of systemic lupus erythematosus according to ACR or SLICC criteria;
* being affiliated to health insurance;
* willing to participate and to sign informed consent.

Exclusion Criteria:

* pregnant or breastfeeding women;
* persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent

Where it's running

• CHU de Bordeaux - Médecine Interne et Immunologie Clinique
  Bordeaux, France Recruiting

Study contacts

• Principal investigator: Noemie GENSOUS, MD — University Hospital, Bordeaux
• Study coordinator: Noemie GENSOUS, MD
• Email: noemie.gensous@chu-bordeaux.fr
• Phone: (0)5 56 79 58 28

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Effects of anifrolumab on arterial inflammation in SLE patients

  This study tests whether anifrolumab can reduce blood vessel inflammation in people with active systemic lupus erythematosus.

  Recruiting University of Cambridge · Cambridge, Cambridgeshire · NCT07913919

• Home urine testing for people with lupus

  Participants with lupus will try weekly home urine tests in addition to usual care to see if this helps monitor kidney health over a year.

  Recruiting NYU Langone Health · New York, New York · NCT07823478

• CR-402 treatment for refractory autoimmune disease

  This study tests CRT-402, a CD19-targeted CAR-T therapy, in adults with active, treatment-resistant autoimmune diseases like SLE, systemic sclerosis, and inflammatory myopathy to see if it is safe and capable of helping control disease.

  Recruiting Phase 1/2 Myeloid Therapeutics · Nedlands, Western Australia · NCT07778446

• ATG-201 in adults with autoimmune diseases

  This early, open-label study tests ATG-201 in adults with autoimmune diseases to see if it is safe and tolerable, and to get initial clues about how the body handles the drug and its effects.

  Recruiting Phase 1 Antengene Corporation · Bengbu, Anhui and 21 other locations · NCT07732309

• Biomarker tests in adults with lupus to see how kidney disease changes over time

  Researchers will follow adults with lupus to see if blood and urine biomarkers can predict kidney involvement, flares, and treatment responses during routine care.

  Recruiting Oslo University Hospital · Oslo, Oslo · NCT07666711

• Sirolimus added to standard therapy for adults with SLE-associated immune thrombocytopenia

  This trial tests whether adding sirolimus to usual treatment helps adults with SLE-related immune thrombocytopenia see their platelet counts improve.

  Recruiting Phase 2/3 Chinese SLE Treatment And Research Group · Beijing, Beijing Municipality · NCT07657793

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.